Does cirrhosis affect quality of life in hepatitis C virus-infected patients?

Liver International

Volumn 29, Issue 3, 2009, Pages 449-458

  Hsu, Priscilla C ^a,b   Krajden, Mel ^a,b   Yoshida, Eric M ^b   Anderson, Frank H ^c   Tomlinson, George A ^d   Krahn, Murray D ^e,f  

^a BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Liver and Intestinal Research Centre   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Cirrhosis; HCV; HepatitisC virus; Quality of life; Socioeconomic factors

Indexed keywords

ADULT; AGE; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE COURSE; EDUCATIONAL STATUS; EMOTIONALITY; FEMALE; FUNCTIONAL STATUS; HEALTH STATUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCOME; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MENTAL HEALTH; PHYSICAL ACTIVITY; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SOCIAL ASPECT; SOCIAL STATUS; TERTIARY HEALTH CARE;

ADULT; AGE FACTORS; BRITISH COLUMBIA; HEALTH STATUS INDICATORS; HEPATITIS C; HUMANS; LINEAR MODELS; LIVER CIRRHOSIS; MIDDLE AGED; QUALITY OF LIFE; SOCIOECONOMIC FACTORS;

EID: 59849087690     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01865.x     Document Type: Article

References (69)

1. Burak KW, Lee SS. Treatment options in patients with chronic hepatitis C. Can J Public Health 2000; 91 (Suppl. 1): S22-6-S24-8.
2. Teo M, Hayes P. Management of hepatitis C. Br Med Bull 2004; 70: 51-69.
3. Fischer B, Haydon E, Rehm J, et al. Injection drug use and the hepatitis C virus: Considerations for a targeted treatment approach -the case study of Canada. J Urban Health 2004; 81: 428-47.
4. Chong CA, Gulamhussein A, Heathcote EJ, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003; 98: 630-8.
5. Thein HH, Krahn M, Kaldor JM, Dore GJ. Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol 2005; 100: 643-51.
6. Brandt J, Spencer M, Folstein M. The telephone interview for cognitive status. Neuropsychiat Neuropsychol Behav Neurol 1998; 1: 111-7.
7. Barber M, Stott DJ. Validity of the telephone interview for cognitive status (TICS) in post-stroke subjects. Int J Geriatr Psychiatry 2004; 19: 75-9.
8. Debling D, Amelang M, Hasselbach P, Sturmer T. Assessment of cognitive status in the elderly using telephone interviews. Z Gerontol Geriatr 2005; 38: 360-7.
9. Bayliss MS, Gandek B, Bungay KM, et al. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res 1998; 7: 39-55.
10. Gutteling JJ, de Man RA, Busschbach JJ, Darlington AS. Overview of research on health-related quality of life in patients with chronic liver disease. Neth J Med 2007; 65: 227-34.
11. Furlong WJ, Feeny DH, Torrance GW, Barr RD. The health utilities index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med 2001; 33: 375-84.
12. Torrance GW, Furlong W, Feeny D, Boyle M. Multi-attribute preference functions. Health utilities index. Pharmacoeconomics 1995; 7: 503-20.
13. Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis 1987; 40: 593-603.
14. Sherman KE, Sherman SN, Chenier T, Tsevat J. Health values of patients with chronic hepatitis C infection. Arch Intern Med 2004; 164: 2377-82.
15. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002; 21: 271-92.
16. Younossi ZM, Boparai N, McCormick M, et al. Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol 2001; 96: 579-83.
17. Bryce CL, Angus DC, Switala J, et al. Health status versus utilities of patients with end-stage liver disease. Qual Life Res 2004; 13: 773-82.
18. Dan AA, Kallman JB, Srivastava R, et al. Impact of chronic liver disease and cirrhosis on health utilities using SF-6D and the health utility index. Liver Transpl 2008; 14: 321-6.
19. Longworth L, Bryan S. An empirical comparison of EQ-5D and SF-6D in liver transplant patients. Health Econ 2003; 12: 1061-7.
20. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40: 373-83.
21. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity. A critical review of available methods. J Clin Epidemiol 2003; 56: 221-9.
22. Ulcickas YM, Quesenberry CP Jr, Guo D, et al. Incidence of non-Hodgkin's lymphoma among individuals with chronic hepatitis B virus infection. Hepatology 2007; 46: 107-12.
23. Skiest DJ, Rubinstien E, Carley N, Gioiella L, Lyons R. The importance of comorbidity in HIV-infected patients over 55: A retrospective case-control study. Am J Med 1996; 101: 605-11.
24. Zavascki AP, Fuchs SC. The need for reappraisal of AIDS score weight of Charlson comorbidity index. J Clin Epidemiol 2007; 60: 867-8. Epub 2007, 23 March.
25. Greenfield S, Apolone G, McNeil BJ, Cleary PD. The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement. Comorbidity and outcomes after hip replacement. Med Care 1993; 31: 141-54.
26. Cocci C, Bianchi G, Nativio V, et al. Perception of health-related quality of life and psychological status in oldest hospitalized patients without cognitive impairment. Arch Gerontol Geriatr 2004; (Suppl.) 9: 75-84.
27. Harboun M, Ankri J. Comorbidity indexes: Review of the literature and application to studies of elderly population. Rev Epidemiol Sante Publique 2001; 49: 287-98.
28. Gabriel SE, Crowson CS, O'Fallon WM. Comorbidity in arthritis. J Rheumatol 1999; 26: 2475-9.
29. Gabriel SE, Crowson CS, O'Fallon WM. A comparison of two comorbidity instruments in arthritis. J Clin Epidemiol 1999; 52: 1137-42.
30. Stojanovic M, Ilic S, Stefanovic V. Influence of co-morbidity on health-related quality of life in patients treated with hemodialysis. Int J Artif Organ 2006; 29: 1053-61.
31. Miskulin DC, Martin AA, Brown R, et al. Inc. Predicting 1 year mortality in an outpatient haemodialysis population: A comparison of comorbidity instruments. Nephrol Dial Transplant 2004; 19: 413-20.
32. Miskulin DC, Meyer KB, Martin AA, et al. Comorbidity and its change predict survival in incident dialysis patients. Am J Kidney Dis 2003; 41: 149-61.
33. Judd CM, McClelland GH. Data Analysis: A Model Comparison Approach. New York: Harcourt Brace Jovanovich, 1989; 204.
34. Henderson HV, Velleman PF. Building multiple regression models interactively. Biometrics 1981; 37: 391-411.
35. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55.
36. Rubin DB. Estimating causal effect from large data sets using propensity scores. Ann Intern Med 1997; 127: 757-63.
37. Fitzmaurice G. Confounding: Propensity score adjustment. Nutrition 2006; 22: 1214-6.
38. Hill J, Reiter JP. Interval estimation for treatment effects using propensity score matching. Stat Med 2006; 25: 2230-56.
39. Sturmer T, Schneeweiss S, Rothman KJ, et al. Performance of propensity score calibration -a simulation study. Am J Epidemiol 2007; 165: 1110-8.
40. Perkins SM, Tu W, Underhill MG, et al. The use of propensity scores in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf 2000; 9: 93-101.
41. Glynn RJ, Schneeweiss S, Sturmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006; 98: 253-9.
42. Shah BR, Laupacis A, Hux JE, Austin PC. Propensity score methods gave similar results to traditional regression modeling in observational studies: A systematic review. J Clin Epidemiol 2005; 58: 550-9. Epub, 19 April 2005.
43. Weitzen S, Lapane KL, Toledano AY, et al. Principles for modeling propensity scores in medical research: A systematic literature review. Pharmacoepidemiol Drug Saf 2004; 13: 841-53.
44. Hagan H, Thiede H. Changes in injection risk behavior associated with participation in the Seattle needle-exchange program. J Urban Health 2000; 77: 369-82.
45. Cologne JB, Shibata Y. Optimal case-control matching in practice. Epidemiology 1995; 6: 271-5.
46. Nosyk B, Sun H, Li X, et al. Highly active antiretroviral therapy and hospital readmission: Comparison of a matched cohort. BMC Infect Dis 2006; 6: 146.
47. Liu C, Weber K, Robison E, et al. Assessing the effect of HAART on change in quality of life among HIV-infected women. AIDS Res Ther 2006; 3: 6.
48. Merito M, Pezzotti P ICONA Study Group. Comparing costs and effectiveness of different starting points for highly active antiretroviral therapy in HIV-positive patients. Evidence from the ICONA cohort. Eur J Health Econ 2006; 7: 30-6.
49. Price LA, Thombs B, Chen CL, Milner SM. Liver disease in burn injury: evidence from a national sample of 31,338 adult patients. J Burns Wounds 2007; 7: E1.
50. Baser O. Too Much ado about propensity score models? Comparing methods of propensity score matching. Value Health 2006;9: 377-85.
51. Saris-Baglama RN, Dewey CJ, Chisholm GB, et al. SF Health Outcomes Scoring Software User's Guide. Lincoln, RI: QualityMetric Incorporated, 2004.
52. Hopman WM, Towheed T, Anastassiades T, et al. Canadian normative data for the SF-36 health survey. Can Med Assoc J 2000; 163: 265-71.
53. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: Initial catalog of health-state quality factors. Med Decis Making 1993; 13: 89-102.
54. Luo N, Johnson JA, Shaw JW, et al. Self-reported health status of the general adult U.S. population as assessed by the EQ-5D and Health Utilities Index. Med Care 2005; 43: 1078-86.
55. Maddigan SL, Feeny DH, Johnson JA. Health-related quality of life deficits associated with diabetes and comorbidities in a Canadian National Population Health Survey. Qual Life Res 2005; 14: 1311-20.
56. Fryback DG, Dunham NC, Palta M, et al. US norms for six generic health-related quality-of-life indexes from the National Health Measurement study. Med Care 2007; 45: 1162-70.
57. Lawrence WF, Fryback DG, Martin PA, et al. Health status and hypertension: A population-based study. J Clin Epidemiol 1996; 49: 1239-45.
58. Mancuso CA, Peterson MG. Different methods to assess quality of life from multiple follow-ups in a longitudinal asthma study. J Clin Epidemiol 2004; 57: 45-54.
59. Younossi ZM, Boparai N, Price LL, et al. Health-related quality of life in chronic liver disease: The impact of type and severity of disease. Am J Gastroenterol 2001; 96: 2199-205.
60. Ware JE, Bayliss JS, Mannocchia M, et al. Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response. Hepatology 1999; 30: 550-5.
61. Niederau C, Bemba G, Kautz A. Changes in socio-economics, quality of life and knowledge of patients with chronic hepatitis C during the Hepatitis Competence Net Project. Z Gastroenterol 2008; 46: 22-33.
62. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions. Results from the medical outcomes study. JAMA 1989; 262: 907-13. Erratum in: JAMA 1989; 262:2542.
63. Samsa G, Edelman D, Rothman ML, et al. Determining clinically important differences in health status measures: A general approach with illustration to the Health Utilties Index Mark II. Pharmacoeconomics 1999; 15: 141-55.
64. Spiegel BM, Younossi ZM, Hays RD, et al. Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment. Hepatology 2005; 41: 790-800.
65. Hauser W, Zimmer C, Schiedermaier P, Grandt D. Biopsychosocial predictors of health-related quality of life in patients with chronic Hepatitis C. Psychosom Med 2004; 66: 954-8.
66. Mittmann N, Trakas K, Risebrough N, Liu BA. Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics 1999; 15: 369-76.
67. Roberge R, Berthelot JM, Wolfson M. The health utility index: Measuring health differences in Ontario by socioeconomic status. Health Rep 1995; 7: 25-32 (Eng); 29-37.
68. Rizzo JA, Pashko S, Friedkin R, et al. Linking the health utilities index to National medical expenditure survey data. Pharmacoeconomics 1998; 13 (Part 1): 531-41.
69. Braitstein P, Montessori V, Chan K, et al. Quality of life, depression and fatigue among persons co-infected with HIV and hepatitis C: Outcomes from a population-based cohort. AIDS Care 2005; 17: 505-15.